Zelira Therapeutics Ltd: Notice of Investor Webinar - HOPE FDA Program Update
Zelira Therapeutics Ltd: AGM Date and Closing Date for Director Nominations
Zelira Therapeutics Ltd: Appendix 4G
Zelira Therapeutics Ltd: Zelira Receives Positive FDA Minutes from Pre-IND Meeting
Zelira Therapeutics Ltd: Appendix 4C Cash Flow Report
Zelira Therapeutics Ltd: June 2024 Quarterly Activities Report
Zelira Therapeutics Ltd: Zelira secures leading patents for HOPE 1 and HOPE 2
Zelira Therapeutics Ltd: ZLD Advances HOPE Autism Drug Program with U.S FDA Meeting
Zelira Therapeutics Ltd: Zelira Receives USD$1.4Million Unsecured Loan from Chairman
Zelira Therapeutics Ltd: ZLD secures US$1.4M unsecured Chairman loan facility
Zelira Therapeutics Ltd: HOPE SPV receives US$681,000 third tranche of funding
Zelira Therapeutics Ltd: Appendix 4C Cash Flow Report
Zelira Therapeutics Ltd: March 2024 Quarterly Activities Report
Zelira Therapeutics Ltd: Zelira receives $919,000 R&D Tax Incentive Scheme Refund
Zelira Therapeutics Ltd: Appendix 4C Cash Flow Report
Zelira Therapeutics Ltd: December 2023 Quarterly Activities Report
Zelira Therapeutics Ltd: Change of Auditor
Zelira Therapeutics Ltd: HOPE SPV receives US$819,000 second tranche of funding
Zelira Therapeutics Ltd: Change of Director's Interest Notice x 5
Zelira Therapeutics Ltd: Appendix 4C Cash Flow Report
No Data
No Data